Cholecystokinin 2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma: Results of the lumed phase 0a study
C Rottenburger, GP Nicolas, L McDougall… - Journal of nuclear …, 2020 - Soc Nuclear Med
Treatment of patients with advanced medullary thyroid carcinoma (MTC) is still a challenge.
For more than 2 decades, it has been known that the cholecystokinin 2 receptor is a …
For more than 2 decades, it has been known that the cholecystokinin 2 receptor is a …
[HTML][HTML] Radiomics Analysis for 177Lu-DOTAGA-(ly)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer—A Model Based on Clinical …
E Kelk, P Ruuge, K Rohtla, A Poksi, K Kairemo - Life, 2021 - mdpi.com
177Lu-DOTAGA-(ly) fk (Sub-KuE) aka 177Lu-PSMA I&T is currently used for radioligand
therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) in several centers …
therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) in several centers …